Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01748734 · ClinicalTrials.gov registry record · Phase 2

Cognitive Therapy in Reducing Depression in Patients With Cancer

A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target

NCT01748734: Completed Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.

NCT01748734 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01748734, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target

Study Summary

The purpose of this study is to learn about treatment of depression in people who have any type of cancer. Cognitive therapy (CT) helps improve depressive symptoms by targeting patient's thoughts and behaviors. People who are depressed tend to have more negative or pessimistic thoughts. CT helps people evaluate the accuracy of their thoughts. By encouraging patients to develop more balanced views, symptoms of depression begin to improve

Primary Outcome

Only modules for mood disorders, anxiety disorders, and substance use disorders will be used. The Global Assessment of Functioning (GAF) Scale will be included as part of the SCID interview. The Longitudinal Interview Follow-Up Evaluation (LIFE) will be used to assess psychosocial, diagnostic, and treatment information. Alpha level will be set at 0.05, beta at 0.20. 95% confidence intervals will be obtained for all outcome measures.

Interventions

  • OTHER questionnaire administration
  • PROCEDURE quality-of-life assessment
  • OTHER counseling intervention
  • BEHAVIORAL behavioral intervention

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2011-03
Phase Phase 2

What the finished NCT01748734 record still lists

NCT01748734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 4 interventions - of which questionnaire administration is the first listed.

NCT01748734 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01748734 about?

NCT01748734 is a clinical study titled "Cognitive Therapy in Reducing Depression in Patients With Cancer". The purpose of this study is to learn about treatment of depression in people who have any type of cancer. Cognitive therapy (CT) helps improve depressive symptoms by targeting patient's thoughts and behaviors. People who are depressed tend to have more negative or pessimistic thoughts. CT helps peo...

What is the current status of trial NCT01748734?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-03.

What interventions are being tested in trial NCT01748734?

The interventions under investigation include: questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), counseling intervention (OTHER), behavioral intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT01748734?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01748734's enrollment target sits among peer trials

25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01748734, the US trial registry maintained by the National Library of Medicine. NCT01748734 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.